Table 1. Diagnostic profiles of seven selected kiwifruit allergic patients used for the initial characterization of kiwifruit LTPs.

A.
Subjects	InterAll APC Code	Age	Gender	Symptoms°	Total IgE	Skin test*		CAP IgE**	DBPCFC°	ISAC 103 IgE**
						Commercial extract	Prick-Prick	Commercial extract		Act d 1	Pru p 3
1	ITROMIDI28837	26	M	URT	1254	18.00	Neg	Neg	URT	Neg	1.07
2	ITROMIDI21272	40	M	URT	790	Neg	Neg	4.10	URT	Neg	1.01
3	ITROMIDI24698	37	F	OAS	11	43.69	89.05	1.24	URT	Neg	3.61
4	ITROMIDI24232	31	F	GI - URT	65	Neg	29.39	1.02	GI - URT	Neg	1.89
5	ITROMIDI28626	16	M	GI	450	Neg	60.06	3.40	URT	4.34	9.35
6	ITROMIDI1558	28	M	GI - URT	211	56.00	109.11	0.84	GI - URT	Neg	2.70
7	ITROMIDI5272	27	F	OAS	2500	17.34	23.76	7.00	URT	Neg	5.46

Panel A: Tests leading to kiwifruit LTP suspected reactivity are reported.

APC: Allergome Personal Code used in the InterAll e-record.

° Double Blind Placebo Controlled Food Challenge; GI: gastro-intestinal tract symptoms including vomiting and abdominal pain; OAS: oral allergy syndrome; URT: Urticaria.

*Results of skin testing performed with green kiwifruit are expressed as mm².

**ISAC and CAP IgE results are expressed as kU/l.

Panel B: In vivo and in vitro results of kiwifruit LTP testing are reported.

APC: Allergome Personal Code used in the InterAll e-record.

*Results of skin testing are expressed in mm².

**ISAC and CAP IgE results are expressed as kU/l. A streptavidin-CAP has been used for kiwifruit LTP IgE detection.

°° In-house Pru p 3 preparation used throughout the study was immobilized on ISAC Exp96.